These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 39280069)

  • 1. Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism.
    Feng X; Zhang R; Yang Z; Zhang K; Xing J
    J Clin Transl Hepatol; 2024 Sep; 12(9):815-826. PubMed ID: 39280069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic.
    Rao G; Peng X; Li X; An K; He H; Fu X; Li S; An Z
    Front Med (Lausanne); 2023; 10():1294267. PubMed ID: 38089874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Syed-Abdul MM
    Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions.
    Li X; Li M
    Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of natural lipophagy modulators in metabolic dysfunction-associated steatotic liver disease.
    El-Ashmawy NE; Khedr EG; Al-Ashmawy GM; Kamel AA
    Nutrition; 2024 Oct; 126():112517. PubMed ID: 39146583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.
    Leahy C; Osborne N; Shirota L; Rote P; Lee YK; Song BJ; Yin L; Zhang Y; Garcia V; Hardwick JP
    Biochem Pharmacol; 2024 Oct; 228():116241. PubMed ID: 38697309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs.
    Zhu B; Wei Y; Zhang M; Yang S; Tong R; Li W; Long E
    Front Pharmacol; 2023; 14():1286449. PubMed ID: 38027027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways.
    Tamilmani P; Sathibabu Uddandrao VV; Chandrasekaran P; Saravanan G; Brahma Naidu P; Sengottuvelu S; Vadivukkarasi S
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102231. PubMed ID: 37865226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
    Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
    Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
    Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
    Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis.
    Liu Y; Zhao Y; Liu Q; Li B; Daniel PV; Chen B; Wu Z
    J Lipid Res; 2024 Jan; 65(1):100483. PubMed ID: 38101620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review.
    Afonso MB; David JC; Alves MI; Santos AA; Campino G; Ratziu V; Gautheron J; Rodrigues CMP
    Metabolism; 2024 Sep; 158():155975. PubMed ID: 39004396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Polyzos SA; Targher G
    Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.